CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% Drug Patent Profile
✉ Email this page to a colleague
When do Clindamycin Phosphate In Dextrose 5% patents expire, and what generic alternatives are available?
Clindamycin Phosphate In Dextrose 5% is a drug marketed by Abraxis Pharm, Hikma, Abbott Labs, and Baxter Hlthcare. and is included in five NDAs.
The generic ingredient in CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% is clindamycin phosphate. There are fifty-five drug master file entries for this compound. Twenty-nine suppliers are listed for this compound. Additional details are available on the clindamycin phosphate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Clindamycin Phosphate In Dextrose 5%
A generic version of CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% was approved as clindamycin phosphate by ALMAJECT on July 24th, 1987.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%?
- What are the global sales for CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%?
- What is Average Wholesale Price for CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%?
Summary for CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%
US Patents: | 0 |
Applicants: | 4 |
NDAs: | 5 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 33 |
Clinical Trials: | 30 |
DailyMed Link: | CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% at DailyMed |
Recent Clinical Trials for CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Daré Bioscience, Inc. | Phase 1 |
Memorial Sloan Kettering Cancer Center | Phase 2 |
Daré Bioscience, Inc. | Phase 3 |
See all CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% clinical trials
Pharmacology for CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%
Drug Class | Lincosamide Antibacterial |
Physiological Effect | Decreased Sebaceous Gland Activity Neuromuscular Blockade |